Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone

Human Pathology

Volumn 34, Issue 7, 2003, Pages 646-653

  Roudier, Martine P ^a   True, Lawrence D ^b   Higano, Celestia S ^b   Vesselle, Hubert ^b   Ellis, William ^b   Lange, Paul ^b   Vessella, Robert L ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Adenocarcinoma; Autopsy; Bone metastasis; Chromogranin A; Immunohistochemistry; Neuroendocrine; Prostate; Prostate specific antigen

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ANDROGEN; CHROMOGRANIN A; PROSTATE SPECIFIC ANTIGEN;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; AUTOPSY; BONE METASTASIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; GENETIC HETEROGENEITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; MALE; PHENOTYPE; PROSTATE CARCINOMA; PROSTATECTOMY; SAMPLING; TUMOR LOCALIZATION;

EID: 0038721560     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0046-8177(03)00190-4     Document Type: Article

References (28)

1. Jemal A, Thomas A, Murray T, et al: Cancer statistics, 2000. CA Cancer J Clin 52:23-47, 2002
2. Whitmore WF Jr: Natural history and staging of prostate cancer. Urol Clin North Am 11:205-220, 1984
3. Coffey DS: Prostate cancer. An overview of an increasing dilemma. Cancer 150:379-385, 1993
4. Landis SH, Murray T, Bolden S, et al: Cancer statistics, 1998. CA Cancer J Clin 48:6-29, 1998
5. Scardino PT: The Gordon Wilson Lecture. Natural history and treatment of early-stage prostate cancer. Trans Am Clin Climatol Assoc 111:201-241, 2001
6. Blummer G: A report of two cases of osteoplastic carcinoma of the prostate with a review of the literature. Johns Hopkins Hosp Bull 20:200-204, 1909
7. Mintz R, Smith GG: Autopsy findings in 100 cases of prostatic cancer. N Eng J Med 11:481-487, 1934
8. Saitoh H, Hida M, Shimbo T, et al: Metastatic patterns of prostatic cancer. Correlation between sites and number of organs involved. Cancer 54:3078-3084, 1984
9. de la Monte SM, Moore GW, Hutchins GM: Metastatic behavior of prostate cancer. Cluster analysis of patterns with respect to estrogen treatment. Cancer 58:985-993, 1986
10. Lamothe F, Kovi J, Heshmat MY, et al: Dissemination of prostatic carcinoma: An autopsy study. J Natl Med Assoc 78:1083- 1086, 1986
11. Harada M, Iida M, Yamagushi M, et al: Analysis of bone metastasis of prostatic adenocarcinoma in 137 autopsy cases. Adv Exp Med Biol 324:173-182, 1992
12. Bubendorf L, Schopfer A, Wagner U, et al: Metastatic patterns of prostate cancer: An autopsy study of 1,589 patients. HUM PATHOL 31:578-583, 2000
13. Rubin MA, Putzi M, Mucci N, et al: Rapid ("warm") autopsy study for procurement of metastatic prostate cancer. Clin Cancer Res 6:1038-1045, 2000
14. Byar DP: The Veterans Administration Cooperative Urological Research Group's studies on prostatic cancer and its treatment, in Tannenbaum M (ed): Urologic Pathology: The Prostate. Philadelphia, PA, Lea & Febiger, 1977, pp 241-263
15. Rana A, Chisholm GD, Khan M, et al: Patterns of bone metastasis and their prognostic significance in patients with carcinoma of the prostate. Br J Urol 72:933-936, 1993
16. Stein BS, Vangore S, Petersen RO: Immunoperoxidase localization of prostatic antigens. Comparison of primary and metastatic sites. Urology 24:146-152, 1984
17. Ro JY, Tetu B, Ayala AG, et al: Small cell carcinoma of the prostate II. Immunohistochemical and electron microscopic studies of 18 cases. Cancer 59:977-982, 1987
18. Cohen RJ, Glezerson G, Haffejee Z: Neuro-endocrine cells: A new prognostic parameter in prostate cancer. Br J Urol 68:258-262, 1991
19. Oesterling JE, Hauzeur CG, Farrow GM: Small cell anaplastic carcinoma of the prostate: A clinical, pathological and immunohistological study of 27 patients. J Urol 147:804-807, 1992
20. Weinstein MH, Partin AW, Veltri RW, et al: Neuroendocrine differentiation in prostate cancer: Enhanced prediction of progression after radical prostatectomy. HUM PATHOL 27:683-687, 1996
21. Bohrer MH, Schmoll J: Immunohistochemical and morphometric studies on neuroendocrinc differentiation of prostate carcinomas. Verh Dtsch Ges Pathol 77:107-110[in German], 1993
22. Allen FJ, Van Velden DJ, Heyns CF: Are neuroendocrine cells of practical value as an independent prognostic parameter in prostate cancer? Br J Urol 75:751-754, 1995
23. Cheville JC, Tindall D, Boetler C, et al: Metastatic carcinoma to bone. Cancer 95:1028-1036, 2002
24. Reuter VE: Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy. Urology 49: 16-22, 1997
25. Carlier, Davrinche: Les métastases osseuses dans le cancer de la prostate [in French]. L'écho Médical du Nord 340:313-322, 1903.
26. Bumpus HCJ: Carcinoma of the prostate: A clinical study of one thousand cases. Surg Gynecol Obstet 43:150-155, 1926
27. Cheng L, Slezak J, Bergstralh EJ, et al: Dedifferentiation in the metastatic progression of prostate carcinoma. Cancer 86:657-663, 1999
28. Swanson K, True LD, Lin DW, et al: A quantitative model for the dynamics of serum prostate-specific antigen (PSA) as a marker for cancerous growth: An explanation for a medical anomaly. Am J Pathol 158:2195-2199, 2001